Answers are grounded in this paper and cite their sources.
Real-world study finds VMAT2 inhibitors may offer safer outcomes in tardive dyskinesia, suggesting a clinical advantage.
This real-world study suggests that VMAT2 inhibitors may offer a safer therapeutic option than anticholinergic agents for TD management, supporting their potential clinical advantage and the need for further long-term validation.
No takes yet. Share an insight, caveat, or question.
Hsu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: